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ABSTRACT 
 
INTRODUCTION: Carcinoma of the cervix is frequently diagnosed in the department of 
Radiation Oncology in Charlotte Maxeke Johannesburg Academic Hospital(CMJAH). It is  
therefore is a condition of priority and there is scarce literature in the management of HIV 
positive patients. 
 
OBJECTIVES: The primary objective of the research is to determine the overall survival of 
2yrs and more, as well as to determine acute and late toxicity for patients completing 
prescribed radiation treatment. The secondary objective was to determine the impact of 
highly active antiretroviral therapy on survival and toxicity. The study is limited to HIV 
positive women presenting with cervical cancer.  
 
DESIGN & METHOD:  The study is a retrospective study of patients treated at Charlotte 
Maxeke Johannesburg Academic Hospital between 2008-2009. 
Inclusion criteria: Females between the ages of 18 and 70, Stages IB2 – Stage IIIB carcinoma 
of the cervix who have completed planned radiation therapy with or without chemotherapy. 
The sample size was 151 patients.  
 
RESULTS: The mean age was 42.7yrs.  The median CD4 count was 309 and 26.2% had 
CD4 counts below 200.The majority of patients had either Stage IIB (55.0%) or IIIB 
(31.8%). The total dose to Point A was a median dose of 74Gy.   The majority of patients had 
either Grade II (38.4%) or III (31.1%) toxicity. Significant association between these adverse 
events and HAART status was rated as p=0.0008. The most common late complication was 
cystitis (15.9%). Overall survival at 2 years was 100% for Stage I, 92.8% for Stage II and 
96% for Stage III. 
  
CONCLUSION: The median age was lower than in the HIV negative patients. The acute 
complications for those not on HAART, were higher in comparison to patients on HAART. 
The overall survival at 2 yrs. was above 90% for all stages in this study cohort. 
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Definition of terms used in this study: 
 
Term  
 
Definition  
 
Alive  All patients who are alive two years after 
treatment (living with nor  without the disease)  
 
Dead  All patients who had died or we were unable to 
follow up on before 31 December 2008.  
 
Age  Date of birth to date of registration. 
  
Treatment duration days  Treatment Start Date – Treatment End Date  
 
Waiting period  Date of Diagnosis – Treatment Start Date  
 
Last follow up date  Date last seen alive at the clinic post treatment.  
 
Local failure Generally as a lack of response or clinical 
deterioration in the area that was treated with 
radiation. 
 
  
Point A  
 
The major critical point for dose specification 
of intracavitary brachytherapy, is measured 
2cm above cervical os and 2cm lateral to 
central tandem. 
 
 
Acute toxicity 
 
Adverse events occurring from the treatment 
within 90 days. In this study GIT, GUT and 
skin reactions graded according to 
RTOG(Appendix 1) 
 
Late toxicity 
 
Adverse events from treatment 90 days and 
after.  These include for this study: cystitis, 
proctitis, RVF VVF. 
 
Cystitis  
 
Inflammation of the urinary bladder. It is 
often caused by infection and is usually 
accompanied by frequent, painful urination. 
 
 
Overall survival The length of time from either the date of 
diagnosis or the start of treatment for a 
disease, that patients diagnosed with the 
disease are still alive. 
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ABSTRACT 
 
Carcinoma of the cervix is an important cancer in our department and there is scarce 
literature on the management of HIV positive patients. The primary objectives of the research 
is to determine the overall survival of HIV positive patients at 2 yrs.  and more, as well as 
acute and late toxicity for patients completing prescribed radiation treatment in the 
department of Radiation Oncology. 
 
The secondary objective was to determine the impact of HAART on survival and toxicity. 
The study is limited to HIV positive women presenting with cervical cancer. This was a 
retrospective study of patients treated at CMJAH over a 2 year period. This included patients 
between the ages of 18 and 70, with Stages IB2 – Stage IIIB carcinoma of the cervix.  
Completion of planned radiation therapy with or without chemotherapy.  
 
The sample size was 151 patients with age was 42.7yrs.  The median CD4 count was 309, 
26.2% had CD4 counts below 200.The majority of patients had either Stage IIB (55.0%) or 
IIIB (31.8%). Majority of patients had either Grade II (38.4%) or III (31.1%) toxicity. 
Significant association between these adverse events and HAART status (p=0.0008).  
The most common late complication was cystitis (15.9%).  
 
CONCLUSION: The age seen in this study cohort is lower than that seen in HIV negative 
patients. The acute complications for those not on HAART, were higher in comparison to 
patients on HAART. The overall survival at 2 yrs. was above 90% for all stages in this study 
cohort. HAART also impacted on toxicity in this study cohort. 
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INTRODUCTION: 
 
At present, there are approximately 5.7 million people living with HIV/AIDS in South 
Africa, of which 60% are women. Cervical cancer is the commonest cancer in African 
(black) women who reside in South Africa with a prevalence of 22 per 100 000. It forms 
17.76% of all female cancers(1).  Since 1997, more than 33 000 women have died of cervical 
cancer in South Africa (approximately 3000 per year). In addition, approximately 7000 
women will develop the disease every year (2). 
 
Carcinoma of the cervix has been classified as an acquired immunodeficiency syndrome 
(AIDS) defining disease in patients who are HIV positive (3). With the HIV pandemic in 
Africa, there has been a change in the pattern of presentation. The patients are presenting at a 
younger age with locally advanced and metastatic disease. They also  have shorter duration of 
symptoms and poor differentiation of tumor(4). 
 
A study done in Johannesburg showed that HIV positive patients presented with cervical 
cancer almost 10 years earlier than the HIV negative patients.  The mean age was 44 yrs. vs. 
53 yrs(5). The researchers also showed that patients with CD4 counts less than 200/mm3 had 
significantly more advanced stage disease when compared to HIV negative patients.  
However, it has been shown that radical chemo radiation in conventional doses can be given 
safely to patients who are HIV positive (6).  A study done in Cape Town showed that HIV 
positive patients do far worse than HIV negative patients because of later presentation and a 
decreased likelihood of completing treatment (7). This conveys the importance of completing 
radiation treatment for better outcomes.  
 
The use of HAART is associated with improved outcome in HIV infected females with 
cervical neoplasia (8).  This has also been shown in other studies looking at the role of 
HAART and impact in lymphoma patients(9). The study showed that viral load decreased as 
soon as HAART was initiated. 
 
The standard of treatment for carcinoma of the cervix depends on the stage of the cancer 
(Appendix 1). The treatment for Stage 0-stage IB1 is surgical. From stage IB2 to Stage IV the 
standard of care is concurrent chemo-radiotherapy in the pre- HIV era (10).  This was using 
cisplatin as the chemotherapeutic radiosensitizing agent. Multiple randomized trials have 
shown efficacy of chemotherapy when added to radiation, however the addition of cisplatin 
increases the risk of hematological, renal, and gastrointestinal toxicities (Appendix 2).  
A systematic review found that there are no standard guidelines for HIV positive patients, 
therefore these patients were managed like their HIV negative counterparts (11). There is a 
bias in using chemotherapy in patients who have a CD4 count more than 200. This is based 
on a trial done in patients with anal cancer(12).  This trial showed that patients with a CD4 
count more than 200 had excellent disease control and acceptable morbidity as compared to 
patients with a CD4 count <200.cells/mm3.   
 
The most commonly reported problem in faced by researchers was that HIV positive patients 
who could not receive the recommended dose of chemotherapy. 
Hammad et al. found that only 45 % of HIV positive patients completed chemotherapy as 
compared to 89% of HIV negative patients with anal cancer(13). 
 
The recommended dose of Cisplatin chemotherapy is 40mg/m2 weekly concurrently with 
radiation.  In a Phase 1 study done in Johannesburg, the authors reported that a weekly dose 
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of 25mg/m2 of Cisplatin was the maximum tolerable dose(14) . This was significantly lower 
than the recommended dose. The following factors were found to be a reason for the lowered 
dose: inherent renal dysfunction, advanced stage cancer, chronic infections, dehydration and 
volume depletion, drug related factors, limited medical facilities.  It was noted that in this 
study, the HIV status of the patients was not evaluated separately. 
  
Chemoradiation reduces the CD4 and T-cell count drastically, which decreases the chances of 
survival if the patient is HIV positive, because AIDS is induced with a dramatic fall in CD4 
and T-cell count(15).  
 
The total treatment of more than 6 weeks also has a significant adverse effect on survival 
especially for Stage III patients(16). Prolongation of treatment time in patients with Stage IB, 
IIA, IIB, and III carcinoma of the uterine cervix has a significant impact on pelvic tumor 
control (17). 
Fowler et al. have reviewed 12 retrospective studies and found a 3-25% decrease in local 
control by lengthening the treatment time by one week in head and neck cancers.(18). This is 
because the potential doubling time for head and neck cancers are similar to cervical cancers 
and therefore a comparison might be drawn from these studies(19). 
 
Hemoglobin level has also been found to be a significant prognostic indicator. Several large 
retrospective reviews have found correlations between anaemia during radiation and local 
failure (20)(21). A study done in Johannesburg by Majeed et al showed that patients with mid 
treatment HB of >=12g/dl had significantly lower pelvic failures and  higher 5yr overall 
survival(22). Girinski et al found that even brief periods of severe anaemia(<10g/mL) during 
radiation therapy were associated with increased risk of local failure (23).  Serkies et al found 
that median overall survival in patients with initial Hb >or=12 g/dl was 66 months compared 
to 22 months in those with lower baseline Hb levels (p = 0.0001). Baseline Hb >or=12 g/dl 
was also associated with longer disease-free survival and improved local control. Declining 
Hb level during radiotherapy predicted for improved 5-year disease-free survival and local 
control probability (24).  
 
The use of HAART simultaneous with chemotherapy drugs has high potential for drug-drug 
interactions. These may result in chemotherapy or HAART drug concentrations in the blood 
that are higher or lower than expected, leading to more side effects or reduced efficacy. 
However, there has not been much data published with regards to interactions with Cisplatin 
and HAART.  However what has been seen in this study is that the patients may have 
immunosuppressive effects such at leukopenia, cutaneous side effects complicated by fungal 
infections and diarrhea (25).   
 
Perez et al looked at the dose to point A and the effect of treatment outcome (17). Lanciano et 
al showed that the dose with the highest rate of complications was one exceeding 85Gy (15).  
That study also showed that the use of intracavitory radiation is the single most important 
treatment factor with respect to survival and pelvic control for Stages, II, III.  In our study all 
the patients completed the recommended treatment. The American Brachytherapy Society 
recommends that dose to point A should be equal or more than 85Gy(26). 
Another interesting component in patients with HIV is whether HIV increases the sensitivity 
of cells with radiation. A cellular basis for radiosensitivity is supported by findings that 
fibroblasts from the skin of HIV patients with Kaposi’s sarcoma are more sensitive to 
ionizing radiation when compared to those of healthy controls(27). One proposed explanation 
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for this is that HIV induces a systemic glutathione deficiency leading to a depletion of radio 
protective thiols and increased oxidative stress(28).  However, it remains to be seen whether 
these in vitro effects in fact contribute to increased radiation sensitivity in HIV-infected 
patients.  
A study done at the Tata Memorial Hospital in India, found that in HIV positive patients, 
50% of patients receiving radiation therapy achieved a complete response. Palliative 
fractionated radiation therapy was also effective for patients in poor performance status and 
locally advanced carcinomas in relieving the symptoms associated with carcinoma of the 
cervix. However, there was a high rate of toxicity seen, especially acute gastrointestinal and 
acute skin toxicity(29). 
 
Five year overall survival for the present study done by Logar et al was 47.2%(30).  They 
found that the Point A dose and histology influenced the outcome. Shrivastava et al described 
a study group of 42 HIV positive patients and 50% had complete response at 6 weeks follow 
up, although with high toxicity rates (29). For all stages of cervical cancer, the five-year 
survival rate is 68%. When detected at an early stage, the five-year survival rate for women 
with invasive cervical cancer is 91%(31). 
 
CMJAH sees about 700 new patients of cervical cancer yearly. About 30% of patients are 
HIV positive. There is a scarcity of data looking at HIV positive patients and their outcomes 
available. The primary objective of this analysis was to look at this cohort of patients to 
determine the overall survival at 2 years after completion of radiation and also to determine 
early and late toxicity. The secondary objective was to determine if patients who started on 
HAART will have better outcomes in terms of survival than those patients who did not get 
initiated. 
 
The study looked at the epidemiology, variables such as total treatment time, haemoglobin 
level, dose to point A, the effect of chemotherapy and highly active anti-retroviral therapy 
(HAART) added to radiation and the toxicities relating to radiation therapy. The study was 
limited to HIV positive women presenting with cervical cancer. South Africa is unique 
because it has one of the highest HIV prevalence in the world. 
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MATERIALS AND METHODS 
 
This is a retrospective study looking at patients treated at CMJAH between 2008-2009. The 
data came from files of the patients treated in that period. 
 
Inclusion criteria: 
 
1)  Females between the ages of 18 and 70 
 
2) Stages IB2 – Stage IIIB carcinoma of the cervix 
 
3)   HIV positive patients 
 
4)  The patients must have completed the planned radiation therapy (external beam with 
or without brachytherapy) with or without chemotherapy 
 
Exclusion criteria: 
 
1) Patients treated at Johannesburg Hospital from other African countries as these 
patients will not have follow up in South African  hospitals 
 
2) HIV negative females with carcinoma of the cervix  
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FIGURE 1  
 
 
Sample size calculation using Strat software: 
This is measured as a proportion.  Since we do not know what this proportion might be (from 
a pilot study or from literature), we make a worst case assumption that the proportion is 50%.  
To estimate this proportion with a 5% precision requires a sample size of 385, given by the 
sample size calculation for the estimation of proportions. 
 
The sample size of 153 used in this study is considerably lower than what was calculated and 
would lead to the estimation of a 50% proportion with only ~8%, rather than 5% precision. 
 
Radiation therapy technique:  
 
External beam radiation therapy 
Patients included in the study received whole pelvic radiation therapy at mid pelvic 
dose per fraction of 2 Gy to a total dose of 46 Gy-50Gy in 23 -25 fractions respectively for 5 
days /week. 
 
The field size was determined at 2 Dimensional(2D) simulation.  
 
AP/PA fields 
Superior border – Mid L5 vertebra 
Inferior border -No vaginal involvement - Bottom of obturator foramen 
 Vaginal involvement less than two thirds - Bottom of ischial tuberosity flower 
half of vagina involved, this was marked and the lower border of the field 
placed 2 cm below the mark. 
 
Lateral borders 
1.5-2cm beyond the pelvic rim, unless the lower 1/3 of the vagina involved, the 
inguinal nodes were treated to beyond the acetabular margin. 
 
0
50
100
150
200
250
300
350
2008 2009
2008 versus 2009 Patients Treated
Total Seen Total Treated
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FIGURE 2: AP/PA simulation film, Lateral brachytherapy insertion radiograph, Anterior-
posterior brachytherapy insertion radiograph 
 
 
Brachytherapy 
Three intracavitary applications with High Dose Rate Brachytherapy, with the Dose 
prescribed to point ‘A’, were given. In most of the patients a rigid intrauterine tandem 
(Nucleotron (trademark) 6cm, 4cmor 2cm in length) and a ring applicator (Nucleotron 3.4cm, 
3cm or 2.6cm in diameter) were used with a rectal shield. If the tumour involved more than 3 
cm of vagina, a Joss Flynn applicator was used to treat up to 4 cm of the vagina. If the 
tumour infiltrated further down the vagina, the treatment was individualized. 
  
Evaluation of Toxicity 
Patients were evaluated for toxicity weekly during treatment using the RTOG/WHO 
common toxicity criteria (Appendix C). Acute side effects were those occurring 
during treatment and within 90 days’ post treatment.  
 
Criteria for response 
All responses were measured clinically. Response to treatment was classified as 
complete or incomplete. A complete response was defined as the complete 
Disappearance of all gross disease at 3 months post completion of treatment. 
Incomplete response was defined as the presence of disease based on physical 
examination findings. 
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METHODOLOGY 
 
The sample comprised one hundred and fifty-one (151) adult female HIV positive patients 
with cervical cancer who were registered to start radiotherapy at CMJAH in the period 2008-
2009 
 
The analysis was done using STATA version 13.  To fulfill the objective of the description of 
demographic characteristics, frequency tables were compiled for the category variable and 
appropriate central tendency measures were computed for the continuous variable.  The 
results for the description of demographic characteristics are presented in tables 3 and 4. 
 
The effect of HAART on acute skin reaction was fitted with an ordinal logistic regression 
univariate and multivariate model, after running a proportional odds assumption test.  The 
ordinal logistic regression model was used because the outcomes were ordered. 
 
 
RESULTS 
The Shapiro Wilk test for normality was used to assess the distribution of age.  Age was 
found to be nominally distributed and hence were reported. 
 
TABLE 1    
PATIENT 
CHARACTERISTIC FREQUENCY % 
AGE MEAN: 42.67YRS SD=8.48 
   
HISTOLOGY TOTAL =149  
SCC 139 92.7% 
ADENOCARCINOMA 10 2.60% 
   
STAGE TOTAL N = 151  
IB2 11 7.28 
IIA 8 5.30 
IIB 83 54.97 
IIIA 1 0.66 
IIIB 48 31.79 
   
HAART INITIATED TOTAL N = 146  
YES 34 22.52 
NO 112 73.20 
   
CHEMOTHERAPY GIVEN   
YES 4 2.60 
NO 147 85.60 
   
CD4 COUNT   
<200 34 22.52 
>=200 112 77.48 
HAEMOGLOBIN BEFORE 
DXT   
<10 146 96.69 
>=10 5 3.31 
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The mean age reported was 42.67 years.  This was in keeping with other studies seen in HIV 
positive patients.  The Histology most commonly seen was squamous cell carcinoma (92.7%) 
compared to adenocarcinoma (2.60%).  The commonest stage seen was stage IIB(54.97%) 
followed by stage IIIB (31.79%).   
 
Of the 34 patients who were known to have been initiated on HAART, 38.20% (n=13) were 
initiated before the start of radiation therapy, and 61.80% (n=21) after the start of radiation 
therapy. No statistical evaluation could be done due to the small numbers in subgroup. 
 
 
 
Chemotherapy status:  The chemotherapy status of 10.6% of the patients were unknown.  
Only 4 patients (2.6%) were known to have undergone chemotherapy, while the rest (n=147) 
did not receive chemotherapy. The reasons for not receiving chemotherapy Stage IIIB disease 
(n=48) CD 4 count < 200 (n=34), and abnormal renal function. 
 
 
Radiation technique.  All the patients (n =151) had AP/PA simulation. 
Brachytherapy was given with a ring applicator in 143(95.97%) of 
patients.  Joslin application was given to 6(4.03%) patients 
 
CD4 count was divided into 2 groups.  The majority of patients had a \CD4 count above 200 
(77.48%). 
The majority of patients had a Haemoglobin level less than 10g/dl prior to radiation(96%).   
 
 
 
TABLE 2 (Appendix 3 reference) 
 
TREATEMENT 
CHARACTERISTICS  
FREQUENCY  % 
ACUTE SKIN REACTION   
NONE 34 22.67 
GRADE 1 10 6.67 
GRADE 2 58 38.67 
GRADE 3 47 31.33 
GRADE4 1 0.67 
   
ACUTE GUT REACTION   
NONE 84 56.00 
GRADE 1 29 19.33 
GRADE 2 37 24.67 
   
ACUTE GIT REACTION   
NONE 93 62.00 
GRADE 1 24 16.00 
GRADE 2 32 21.33 
   
LATE TOXICITY   
PROCTITIS 14 9.46 
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CYSTITIS 24 16.22 
VVF 5 3.38 
RVF 4 2.70 
NONE 101 68,24 
   
TREATMENT DELAY   
<6 WEEKS 12 7.94 
>=6 WEEKS 139 92.05 
   
TREATMENT TIME   
<6 WEEKS 80 52.98 
>=6 WEEKS 71 47.02 
   
FAILURE SITE   
LOCAL 9 5.96 
BRAIN 1 0.66 
LUNG 0 0.00 
BONE 4 2.65 
   
   
   
TOTAL DOSE: POINT-A MEAN = 73.76GY SD = 7.60 
   
 
The most commonly seen acute skin reaction was grade 2 (38.67%). Acute toxicity: there 
was no difference for acute skin reaction (p=0.635), GUT (p=0.073) and GIT (p= 0.223) 
 The most common late complication was cystitis (16.22%)  However these results must be 
interpreted with caution as most of the patients (68.24%) were lost to follow up and therefore 
were not able to be included.  There was a treatment delay of more than 6 weeks in 92.05% 
of patients and this contributes to the outcomes.  The most common failure site was local in  
5.96% in those patients that did follow up. 
 
TABLE 3 
 
UNIVARIATE    MULTIVARA
TE 
  
CHARACTERISTIC OR P-
VALUE 
CI OR P-
VALUE 
CI 
ACUTE SKIN 
REACTION : 
BASE=ON HAART 
      
   NOT ON HAART 0.84 0.635 0.41-1.73 0.92 0.645 0.64 -
1.32 
       
ACUTE GUT 
REACTION 
      
   NOT ON HAART 1.98 0.073 0.94 -4.17 1.65 0.088 0.93 -
2.93 
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ACUTE GIT 
REACTION 
      
   NOT ON HAART 1.63 0.223 0.74 -3.59 1.33 0.313 0.76 – 2. 
       
LATE TOXICITY       
  NOT ON HAART 3.27 0.002 1.53 -7.01 1.46 0.003  
       
       
       
 
 
This above figure showed that patients who were not initiated on HAART had a 1.98 chance 
of having acute GUT reactions while on radiation treatment.  The most significant (p value 
0.002) variable seen was that patients not on HAART who were 3 times more likely to have a 
late toxicity than those patients who had started HAART treatment. 
 
 
 
 
 
 
 
FIGURE 3 
 
 
Survival analysis:  This was done taking the last day they were seen as alive, dead and 
treatment failure which were negative events.  When treatment failure came before the date 
last seen, the number of months to treatment failure was used. 
The Kaplan Meyer graph was used to assess the overall cancer related deaths.  This was then 
analyzed to look at patients who initiated HAART, and by Stage 
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FIGURE 4 (Analysis time in months) 
 
This graph shows that overall survival seen in this study cohort was 47 months in 70 % of 
patients.  
 
 
FIGURE 5 (Analysis time in months) 
 
The above graph shows that there was not much difference seen in survival in patients who 
had initiated HAART treatment to those who did not start HAART especially in the first 15 
months following therapy.  Between 15 and 20 months following therapy, the trend showed 
better survival in patients who had initiated HAART.  This levelled out for patients on 
HAART, but the survival dropped for patients not on HAART at 45 months. 
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FIGURE 6 
The graph above shows that Stage was also important in terms of survival.  Those patients 
who were stage IIIB had a trend for poor survival than patients who were Stage IIB when 
looking at 12 to 48 months after treatment.  These Stages were the most common stages seen 
in this study cohort. 
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DISCUSSION 
 
 
This study had important questions to be answered when managing a special cohort of 
patients with HIV. Review of patients while on treatment is important, and ideally should be 
consistent either by using one doctor or by having a standard form.   There were limitations 
to the study that limited these vital answers.  The most important was follow up.  The use of 
patient files, with numerous doctors seeing the patients, meant that there was no uniformity in 
assessing the acute reactions.  The patients lost to follow up was why the results for overall 
survival could not be used with any accuracy. 
 
 
The standard of care for the treatment of cancer of the cervix is concurrent chemo-
radiotherapy for the best outcomes. In our study, the majority of patients (85.6%)did not 
receive chemotherapy, with only 4 patients (2.6%) receiving chemotherapy. Therefore a 
comparison between patients receiving chemo-radiotherapy and radiotherapy alone could not 
be made.  Reasons for not giving chemotherapy were mainly based on the fact that the renal 
function was not suitable for chemotherapy.   
 
There is a bias in the  use of chemotherapy in patients who have a CD4 count more than 200. 
This is based on a trial done in patients with anal cancer (16).  This trial showed that patients 
with a CD4 count >than 200 had excellent disease control and acceptable morbidity as 
compared to patients with a CD4 count <200.  In our study the median CD4 count was 309, 
and 26.2% of patients had a CD4 <200. The departmental protocol is that chemotherapy is 
excluded for patients with Stage IIIB cervical cancer, due to the lack of benefit seen in these 
patients(32). 
 
 The most commonly found problem was that HIV positive patients did not complete the 
recommended dose of chemotherapy(13). 
In this study, the inclusion criteria were that patients must complete their treatment.  
 
The demographic information was found to be similar between this study group and other 
studies done in developing countries. The median age at registration in this study was 41yrs 
(Range 26-67yrs).  This was also found by Lomalisa et al, their study showed that HIV 
positive patients presented 10 yrs. earlier than their HIV negative counterparts (44yrs vs 
53yrs) (5).  A study by Gighangi et al from Kenya showed that their patients presented 5yrs 
younger as compared to HIV negative patients (19).  
 
The stage of the cancer is also an important variable when predicting outcomes for HIV 
positive patients.  In our study the majority of patients had either stage IIB (55%) or stage 
IIIB (31.8%).  This is in line with other studies which have found that HIV positive patients 
present at advanced stages of the disease.  Mainman et al found that 71% of patients had 
clinical stage II or more when compared to 37% of HIV negative patients in a study of 115 
patients. There was no HIV patient who presented with early stage disease (stage 1A or IB) 
(20).  The advanced stage of disease can also be correlated with CD 4 count.  Lomalisa et al 
found that patients with CD 4 count <200 were significantly more likely to have advanced 
stage disease at diagnosis (5).  In our study there was no correlation between the CD4 and 
advanced stage.  
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Haemoglobin is also a prognostic factor for patients with cancer of the cervix.  This is 
because tumour hypoxia is a potential mechanism of resistance to radiation in bulky cervical 
tissues.  In our study the hemoglobin levels at the start of treatment was >11g/dl for the 
majority of patients (45%) and <10g.dl was 15%.  The haemoglobin levels at 3 weeks during 
radiotherapy had 56.3% of missing data and therefore could not be analyzed.  In the 
department we accept haemoglobin levels above 10g/dl prior to treatment of cervical cancer 
with radiation.  Those patients who have haemoglobin levels < 10g/dl are transfused. 
 
In our study only 22.2% of patients were initiated on HAART at some point during their 
treatment. Of the 34 patients who had started HAART, 13(38.2%) were initiated prior to 
radiation therapy and 21(61.8%) started after radiation therapy was commenced.  Due to the 
small group size obtained this did not translate to any meaning correlation on the impact of 
initiating HAART and outcomes.  
 
There was a delay between registration and the start of treatment.  The median time to delay 
was 3 months.  The median treatment duration was 5 weeks for the majority of patients 
(75%) The reasons for prolonging treatment were treatment breaks due to toxicity.  The 
longest total treatment time was 10 weeks. An extended treatment time of more than 6 weeks 
has been shown to have a 14 % decrease in local control over 4 years especially in stage IIIB 
which was seen in 31.8% of patients in our study (10).  
For this study, it was difficult to look at the effect of treatment time and local failure, due to 
the lack of proper follow up in the study cohort.  
 
It is important to note that while the cell kinetics in head and neck cancers and cervical 
cancer may be similar, there is a component of using brachytherapy in addition to external 
beam radiation in the treatment of cervical cancer.  This means that an increased radiation 
dose can be given to the tumour to compensate for the accelerated repopulation that can 
happen when treatment is prolonged.  It has been shown that completing brachytherapy is 
essential in getting better outcomes (7). This is important then when looking at the total dose 
received by point A. The average dose given to Point A was 74Gy in our study which was 
below what is recommended by the American Brachytherapy association (26). Therefore we 
need to look at this closely to see the impact of a decreased total dose and on outcomes 
especially in HIV positive patients with cervical cancer. 
 
The improvement of total dose can be done by optimizing the brachytherapy technique.  In a 
study done by Niel et al, they found that by adapting the existing high dose rate applicator, 
they could get higher dosimetric accuracy and more adequate irradiation(27).  
 
In terms of the acute and late complications, Gichanji et al looked at the HIV impact on acute 
toxicity and pelvic tumour control. He found that HIV infection was associated with a 7-fold 
higher risk of multisystem toxicity: skin, gastrointestinal tract (GIT) and genitourinary tract 
(GUT) systems. It was also an independent risk factor for treatment interruptions(30). 
However, in this study, the patients did not receive any brachytherapy due to constraints, and 
only received external beam radiation.  In our study most patients had Grade II acute 
reactions to skin, GUT, GIT.  
 
Long term side effects were difficult to access due to the lack of follow up in our patients. In 
studies done by Kapp et al, they found that all severe bowel complications occurred within 
1.5 years whereas urinary tract sequelae continued to develop throughout the follow-up 
period. FIGO stage was associated with a significant increase in late sequelae (29).  The 
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probability of late toxicities of any grade found in a study by Logar et al were 16.6% for 
gastrointestinal, 15.7% for genitourinary and 22.3% for the vagina in the first 5 yrs. of 
treatment.  The mean interval before developing the late complications was 27.6 months(31). 
It is worth noting that in this study they used 2D (2 dimensional) treatments as we do in our 
unit, and their mean dose to point A was 66.5Gy which is lower than the dose used by our 
department.  It may be possible that we would perhaps anticipate similar results should we do 
a prospective study in our patients. 
 
The effect of these long term side effects on the quality of life has been looked at by Kuku et 
al (32). They found that women with cervical cancer were younger and appeared to suffer 
more severe symptoms of late bowel toxicity, which impacted negatively on their quality of 
life. 
 
In terms of overall survival, in our study, this was difficult to ascertain with certainty due to 
the lack of follow up in the study group, therefore there was a lot of missing data.  When 
looking at the results where all patients are alive, overall survival is above 90%.  The follow 
up in our department is done by taking 2 telephone numbers from the patient. They are given 
dates and contacted should they not arrive for the treatment itself. During follow up after 
completion of treatment, patients are not called if they do not arrive on their expected date. 
This would have to be changed for data to be collected. 
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LIMITATIONS AND SUGGESTIONS TO IMPROVE: 
 
Limitations included  
 Incomplete data in the files.  
 Inability to compare certain aspects of the study.   
 No information regarding the type of HAART initiated.  
 Patients were lost in follow up.  This made it difficult to know the overall 
survival with any accuracy. 
 
Suggestions include:  
 A standard form for clerking and review while on treatment. 
 A way to contact patients when they do not arrive for follow up. 
 A booking system might be useful. 
 A prospective study to further evaluate this group of patients with accuracy 
and for a study in outcomes with radiation. 
 
CONCLUSION: 
 
The study showed that HIV positive patients do tolerate the radiation treatment well. The 
acute side effects of radiation were easily treatable, and no prolonged treatment breaks took 
place. They are able to complete the prescribed radiation treatment that is recommended.  
They are, however, have 3 times more chance of developing late radiation toxicities without 
the addition of HAART.  The overall survival with available information was above 90% for 
the study cohort. Further prospective studies are needed.  
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APPENDIX 5: clinical research form 
CODE NO: 
 
AGE AT PRESENTATION: 
 
IS HAART INITIATED? 1: YES, 2: NO                                                DATE STARTED: 
 
CD4 COUNT BEFORE TX: 
 
CD4 COUNT AT F/U: 
 
STAGE: 
 
REGISTRATION DATE: (YYYY/MM/DD) 
 
DATE 1ST TREATED (YYYY/MM/DD) 
 
DATE LAST TREATED (YYYY/MM/DD) 
 
 
HB AT START OF TREATMENT:                                                                     HB AT 3/52:    
                                    
RADIATION GIVEN:                        
 
TOTAL DOSE:                                                                  EXT DOSE:                                   
BRACHY: 
 
RECTAL DOSE 1:                                                             RECTAL DOSE 2:  
   
BLADDER DOSE1:                                                          BLADDER DOSE 2: 
 
RADIATION TECHNIQUE:  
 
 RING APPLICATION: 
 
 JOSLIN APPLICATION: 
 
 
ACUTE  TOXICITY:    
                                                
ACUTE SKIN REACTION DATE:                                ACUTE GUT DATE: 
ACUTE GIT DATE: 
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RADIATION RELATED LATE TOXICITY: 
 
PROCTITIS:     
CYSTITIS:         
              VVF:                            
              RVF: 
 
 
FOLLOW UP: 
ALIVE WELL: 
 
TX FAILURE DATE: (YYYY/MM/DD)  
 FAILURE SITE: 
  
                                         
DEMISE:                                             IF YES, DATE:      
                  
 
 
 
 
 
 
